Navigation Links
Chronic Lung Disease - Axentis Pharma Attracts Investment Interest
Date:2/2/2009

ZURICH, February 2 /PRNewswire/ -- Axentis Pharma AG is to present its recent successes in developing and financing a new therapeutic formulation for treating chronic lung disease at the 2nd Annual European Life Science CEO Forum in Zurich, Switzerland. This invited talk comes just three weeks after the company was asked to present its recent achievements at the Biotech Showcase 2009 in San Francisco, USA. Part of the company's ongoing success story is a recent capital increase that was exceptionally well subscribed by existing private investors.

SIX Swiss Exchange AG is Europe's leading stock exchange for life science companies. Its sponsorship of the European Life Science CEO Forum for Partnering & Investing helps make this one of Europe's most exclusive and highly transactional partnering events.

At this year's forum (February 3 - 4) Dr. Susanne Acklin, COO of Axentis Pharma AG, will be presenting the company's recent successes in developing and financing a new therapeutic formulation for treating chronic lung disease. "2008 was extremely successful for Axentis", explains Acklin. "Our lead product ARB-CF0223 - a liposomal formulation of tobramycin, delivered directly to the site of infection via standard nebulisers - produced very satisfying data from a phase I clinical trial; we initiated a clinical phase II trial and a subsequent capital increase was well received - and subscribed - by our existing private investors. We are very happy with the current position of Axentis and consider it the right time to present the company to experienced institutional investors. That's why we are participating here in Zurich."

Dr. Acklin also serves as Vice President Life Sciences at Venture Valuation AG, a leading independent Swiss company specializing in assessing, valuing and monitoring start-up companies. In this position Acklin has valued well over 100 life science companies and recently decided to join Axentis.

The increasing interest in Axentis and its lead product also resulted in a presentation at the Biotech Showcase 2009 in San Francisco by the company's CEO Dr. Helmut Brunar. Amongst the well over 225 companies present at the event, he had the privilege of presenting the company's success. "Our financial position is sufficiently strong that we decided to wait with a major round of financing until early 2010. Now is therefore the right time to present ourselves in the best light to powerful investors. Our lead product ARB-CF0223 - also known as Fluidosome(R) tobramycin - is expected to generate a peak annual turnover of approx. 100 million EUR within five years of market launch. The investment that we will be seeking in early 2010 will see us through until this entry onto the market. I consider Axentis an extremely attractive investment option. The feedback I received in San Francisco certainly confirmed this personal judgment."

The next opportunity to meet representatives of Axentis Pharma at European conferences will be at the BioSquare in Lyon, France, on March 9 to 11.

About Axentis Pharma AG (http://www.axentispharma.com)

Axentis Pharma AG is a Swiss company located in Zurich with a focus on developing therapeutic solutions for respiratory diseases, most prominently cystic fibrosis. Axentis' lead product is in phase II clinical trials. Market registration / approval is expected in 2012.

About Fluidosome(R) technology

Axentis Pharma's Fluidosome(R) technology uses biocompatible lipids endogenous to the lung that are formulated into small liposomes. This nanocapsule platform offers wide-ranging potential to cater to unmet medical needs such as cystic fibrosis and other respiratory diseases. In the case of Fluidosome(R) tobramycin, the interaction between tobramycin and the microbial cell is triggered when the liposomes attach to the outer cell membrane. Tobramycin then penetrates into the inner cell compartment of the microbial cell, which leads to rapid cell death.

About cystic fibrosis

Cystic fibrosis is the most common life-threatening hereditary disease amongst Caucasian populations. The disease is caused by a mutation in the CFTR (cystic fibrosis transmembrane conductance regulator) gene found on chromosome 7. This mutation causes increased secretion deposits on mucous membranes. Lung complications represent the most serious manifestation of the disease - and the reason for the high mortality rate amongst patients. Such complications often involve infection of the bronchi by the bacteria Pseudomonas aeruginosa. Chronic inflammations then cause lung functions to become blocked. In addition to the breakdown of lung tissue, this also leads to bronchiectasis and lung failure.

    For further information, please contact:

    Axentis Pharma AG
    Limmatquai 138
    8001 Zurich
    Switzerland
    T: +41-79-525-6668
    E board@axentispharma.com

    Copy Editing & Distribution:
    PR&D - Public Relations for Research & Education
    Campus Vienna Biocenter 2
    1030 Vienna
    Austria
    T: +43-1-505-70-44
    E contact@prd.at


'/>"/>
SOURCE Axentis Pharma AG
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C
2. Alfacells ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells
3. Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
4. ANA598 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C Infection
5. Pharos Innovations Joins Partnership to Fight Chronic Disease
6. Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at AASLD 2008
7. UKs NICE Recommends Spinal Cord Stimulation for Patients with Chronic Neuropathic Pain
8. New Company to Develop Nutritional Interventions Against Chronic Inflammatory and Infectious Diseases
9. Physician to Implant the CATANIA(TM) Coronary Stent System With Polyzene(R)-F to Treat Chronic Total Occlusion During Live Case at the Paris Cardiovascular Interventions Course (Francophone) 2008
10. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
11. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... 23, 2016  The Biodesign Challenge (BDC), a university ... to harness living systems and biotechnology, announced its winning ... New York City . ... showcased projects at MoMA,s Celeste Bartos Theater during the ... MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), ... free webinar on Performing Quality Investigations: Getting to Root Cause. ... no charge. , Incomplete investigations are still a major concern to the Regulatory ...
Breaking Biology Technology:
(Date:6/1/2016)... , June 1, 2016 ... in Election Administration and Criminal Identification to Boost Global ... a recently released TechSci Research report, " Global Biometrics ... Region, Competition Forecast and Opportunities, 2011 - 2021", the ... billion by 2021, on account of growing security concerns ...
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour ... from the Q1 wave of its quarterly wearables survey. ... receptivity to a program where they would receive discounts ... company. "We were surprised to see that ... LaColla , CEO of Troubadour Research, "primarily because there ...
Breaking Biology News(10 mins):